Track market-moving stories before they get noisy

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. (“Stryker” or the “Company”) (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Stryker and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 8, 2026, Stryker’s CEO disclosed at the Wells Fargo Healthcare Conference that a manufacturing problem affecting inventory supply in its peripheral vascular business, which management had previously indicated was expected to resolve during the third quarter of 2026, in fact remained unresolved and was now expected to persist into the fourth quarter. 

On this news, Stryker’s stock price fell $26.70 per share, or 8.81%, to close at $276.43 per share on September 8, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

Carvana (CVNA - Free Report) ended the recent trading session at $60.39, demonstrating a +1.48% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a loss of 0.02% for the day. Elsewhere, the Dow saw a downswing of 0.35%, while the tech-heavy Nasdaq depreciated by 0.15%.

The company's stock has dropped by 16.03% in the past month, falling short of the Retail-Wholesale sector's gain of 0.63% and the S&P 500's gain of 2.05%.

Market participants will be closely following the financial results of Carvana in its upcoming release. The company plans to announce its earnings on October 28, 2026. On that day, Carvana is projected to report earnings of $0.49 per share, which would represent year-over-year growth of 133.33%. Simultaneously, our latest consensus estimate expects the revenue to be $7.62 billion, showing a 34.95% escalation compared to the year-ago quarter.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $1.67 per share and a revenue of $28.97 billion, signifying shifts of -1.18% and +42.56%, respectively, from the last year.

It is also important to note the recent changes to analyst estimates for Carvana. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.12% lower within the past month. As of now, Carvana holds a Zacks Rank of #4 (Sell).

Investors should also note Carvana's current valuation metrics, including its Forward P/E ratio of 35.55. This signifies a premium in comparison to the average Forward P/E of 15.29 for its industry.

Also, we should mention that CVNA has a PEG ratio of 1.72. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Internet - Commerce industry stood at 1.24 at the close of the market yesterday.

The Internet - Commerce industry is part of the Retail-Wholesale sector. This group has a Zacks Industry Rank of 180, putting it in the bottom 27% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

In the latest trading session, Veeva Systems (VEEV - Free Report) closed at $301.63, marking a +1.95% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.02%. Meanwhile, the Dow lost 0.35%, and the Nasdaq, a tech-heavy index, lost 0.15%.

Shares of the provider of cloud-based software services for the life sciences industry have appreciated by 11.36% over the course of the past month, outperforming the Medical sector's gain of 1.06%, and the S&P 500's gain of 2.05%.

Investors will be eagerly watching for the performance of Veeva Systems in its upcoming earnings disclosure. The company is predicted to post an EPS of $2.33, indicating a 14.22% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $933.79 million, up 15.11% from the year-ago period.

For the full year, the Zacks Consensus Estimates are projecting earnings of $9.22 per share and revenue of $3.69 billion, which would represent changes of +13.83% and +15.35%, respectively, from the prior year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Veeva Systems. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. As of now, Veeva Systems holds a Zacks Rank of #3 (Hold).

With respect to valuation, Veeva Systems is currently being traded at a Forward P/E ratio of 32.09. For comparison, its industry has an average Forward P/E of 32.09, which means Veeva Systems is trading at no noticeable deviation to the group.

Investors should also note that VEEV has a PEG ratio of 0.92 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The average PEG ratio for the Medical Info Systems industry stood at 3.17 at the close of the market yesterday.

The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 83, positioning it in the top 34% of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Neogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 29, 2026, the U.S. Food and Drug Administration (“FDA”) announced that it had issued a warning letter to Neogen “following an investigation that linked a veterinary wound care product labeled as sterile, Neogen Vet HYCOAT (hyaluronate sodium sterile solution), to serious infections and deaths in horses.”  The FDA said that “[t]his incident involved at least 20 horse deaths, making it the largest number of horse deaths ever associated with a quality defect in an FDA-regulated veterinary medical product and the most deaths of any animal species linked to microbiological contamination of an FDA-regulated product labeled as sterile” and further stated that “Neogen initiated a voluntary recall of HYCOAT in late January 2026.” 

On this news, Neogen’s stock price fell $0.99 per share, or 7.22%, to close at $12.73 per share on September 29, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Acadia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 24, 2026, Acadia issued a press release “announc[ing] Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).” Among other data, the Company disclosed that remlifanserin at 60 mg “narrowly missed” the primary endpoint of a clinical tool designed to measure the severity of the disease. 

On this news, Acadia’s stock price fell $3.25 per share, or 12.78%, to close at $22.18 per share on September 24, 2026. 

Then, on September 25, 2026, multiple analysts downgraded Acadia, citing the disappointing trial results. 

On this news, Acadia’s stock price fell $1.50 per share, or 6.76%, to close at $20.68 per share on September 25, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours " or the "Company") (NYSE: CC) and certain officers. The class action, filed in the United States District Court for the District of Delaware, and docketed under 26-cv-01299, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Chemours securities during the Class Period, you have until December 7, 2026 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Chemours offers a range of industrial and specialty chemical products for markets including, as relevant here, refrigeration and air conditioning. Chemours reports financial results from its sales of such products, including Opteon™, a set of refrigeration chemicals with a “near-zero ozone-depletion footprint”, in its Thermal & Specialized Solutions segment.

In December 2020, the U.S. Congress enacted the American Innovation and Manufacturing Act (“U.S. AIM Act”), which directed the U.S. Environmental Protection Agency to reduce the human impact on climate change by overseeing the transition to alternative refrigerants that present a lesser impact to the ozone layer than legacy refrigerants.

At all relevant times, Defendants represented to investors that “[g]rowth in our Thermal & Specialized Solutions segment is supported in part by the adoption of the [U.S. AIM Act] in the U.S.”

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants had materially overstated aftermarket demand for their Opteon products; (ii) demand for such products was decreasing as a result of Defendants’ overselling Opteon products in the preceding fiscal year; (iii) as a result of these undisclosed issues, Defendants’ financial guidance for the 2026 fiscal year was unreliable; and (iv) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

On August 4, 2026, after market hours, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that “[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026.” Management further disclosed “from the Q2 and Q3 perspective, there’s probably about $65 million of aftermarket sales that realistically, you think about like-for-like probably should have been allocated to more of this year.”

On this news, Chemours’s stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

 | Source:

Enovix Corporation

FREMONT, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Enovix Corporation ("Enovix" or the "Company," Nasdaq: ENVX), a developer and manufacturer of advanced lithium-ion batteries, today announced a purchase order from a multinational provider of dual-use drone systems. The initial order is for 100,000 battery units, with deliveries scheduled in the first half of 2027 as the customer scales its use of Enovix cells manufactured at the Company’s TAA-compliant, military-qualified facility in South Korea. Following successful initial deployment, the customer is expected to place follow-on orders for the program in the second half of 2027 and beyond.

“Drone makers need high-performance batteries from a qualified, non-Chinese source now, and this order shows Enovix can deliver,” said Steve Bakos, Chief Revenue Officer and General Manager of Enovix. “It confirms that our technology performs in demanding applications and that our TAA-compliant, in-house manufacturing has real value to customers who need a secure source of supply.”

The order moves one opportunity from the approximately $216 million drone, defense and industrial pipeline Enovix reported on October 12, 2026 into backlog, and is among the Q4’26 purchase orders referenced in that release. The Company expects additional pipeline opportunities to convert into purchase orders in the coming quarters.

About Enovix

Enovix develops and manufactures advanced lithium-ion batteries, including proprietary silicon-anode architectures for smartphones, smart eyewear, defense, industrial and emerging edge-AI applications. Its proprietary silicon-anode battery architecture enables higher energy density and performance in space-constrained devices while maintaining safety and reliability, supporting commercialization across consumer and industrial markets.

Enovix is headquartered in Silicon Valley with facilities in India, South Korea and Malaysia, serving customers globally. For more information visit https://enovix.com and follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or our future financial or operating performance and are identified by words such as anticipate, believe, could, estimate, expect, intend, may, might, plan, possible, potential, predict, project, should, will, would and similar expressions. Forward-looking statements in this press release include, but are not limited to, statements regarding: the announced purchase order, including the quantity and timing of deliveries, the timing of revenue recognition from the order and the customer’s use of our products, and our expectation that the customer will place follow-on orders for the program in the second half of 2027 and beyond; the viability of our technology and the market value of our TAA-compliant in-house manufacturing capabilities; our strategic focus on the drone and defense business; our sales pipeline and our expectation that additional pipeline opportunities will convert into purchase orders in the coming quarters. These statements are based on the current expectations of our management, are not predictions of actual performance, and actual results may differ materially from the future results, performance or achievements expressed or implied by the forward-looking statements.

Risks, uncertainties and assumptions that could cause actual results to differ materially from the results and events anticipated by such forward-looking statements include, but are not limited to: the possibility that the purchase order is modified, delayed, reduced or cancelled, that deliveries do not occur on the expected schedule or that the revenue we ultimately recognize from the order differs from our expectations; the possibility that the customer does not place follow-on orders or that the program does not continue beyond the initial order; the possibility that other opportunities in our sales pipeline do not convert into purchase orders, or convert later or in smaller amounts than we expect; risks related to our ability to execute on our strategic priorities and the possibility that the anticipated benefits of increased focus on drones and defense are not realized; risks related to the outcome of customer testing and qualification activities, including the possibility that our products do not meet required performance thresholds or that such testing is delayed beyond expected time frames; our ability to successfully develop, manufacture and commercialize our battery products and transition to high-volume production; our ability to scale manufacturing operations and achieve expected production capacity and yields; our ability to satisfy applicable government sourcing, regulatory and certification requirements, including TAA and NDAA requirements; risks relating to the FEOC rules, tariffs, export controls and trade policies; the level and timing of customer demand, qualification and adoption of our products across end markets; our ability to enter into and expand commercial agreements, including securing design wins, purchase orders and production contracts; our ability to execute on our business strategy and build and scale our sales and commercial capabilities; lengthy and unpredictable customer qualification and sales cycles, safety considerations, program delays or cancellations and contractual terms, particularly in defense and other regulated markets; risks related to battery performance, reliability and safety; customer concentration in the defense sector and certain consumer technology markets; challenges in forecasting demand, inventory and manufacturing requirements that may result in additional costs and production delays; our history of losses and expectation of continued losses; risks associated with the development and commercialization of products that remain under development and may not be successfully produced at commercial scale; our ability to effectively integrate and derive benefits from acquired businesses; fluctuations in foreign currency exchange rates and interest rates; operational and safety risks associated with manufacturing equipment; intense competition and our ability to keep up with rapid technological change and evolving standards in the battery industry; our ability to attract and retain qualified personnel; the outcome of litigation, regulatory investigations and other legal matters, including the associated legal and other costs; liquidity constraints, capital availability and our ability to service existing debt; our ability to protect and enforce our intellectual property rights; volatility in the trading price of our common stock; changes in tax laws or regulations; the impact of cyber and other information technology or security related incidents on us, our customers or other parties; changes in the political, economic or regulatory environment generally and in the markets in which we operate; and other risks described in the disclosures contained in our filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" sections of our annual report on Form 10-K and quarterly reports on Form 10-Q, and other documents that we have filed, or will file, with the SEC. These documents are available in the SEC Filings section of the Investor Relations page at https://ir.enovix.com and at www.sec.gov. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Accordingly, you should not rely on any of the forward-looking statements. Any forward-looking statements in this press release speak only as of the date on which they are made. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Note Regarding Customer Pipeline and Design Wins

We may refer in this press release and other communications to our “sales pipeline” or “customer pipeline” and “design wins.” Our sales or customer pipeline represents our estimate of the peak annual production value of identified design opportunities for products manufactured in South Korea. A “design win” refers to an opportunity that has been awarded to Enovix but has not yet entered production. Customer pipeline and design win amounts do not represent customer orders, backlog or committed revenue and should not be viewed as forecasts of future revenue. Actual revenue, if any, will depend on a number of factors, including customer qualification, final program awards, production timing, capacity and volumes, and the successful launch and ramp of customer programs. These measures are forward-looking and are subject to the risks and uncertainties described above under “Forward-Looking Statements.”

For media and investor inquiries, please contact:
Investor Contact:
Monica Gould
Blueshirt Group
[email protected]

Source: Enovix Corporation

Prabu Natarajan Named Permanent Executive Vice President of the Civilian Business Group; Kenneth Crews to Join SAIC as Executive Vice President and Chief Financial Officer Elect  | Source: SAIC, Inc.

RESTON, Va., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Science Applications International Corp. (NASDAQ: SAIC) today announced two key leadership appointments intended to strengthen the executive team and position the company for long-term success through accelerated growth and strong execution.

Prabu Natarajan has been named permanent Executive Vice President of the Civilian Business Group, effective immediately, after serving as interim lead for the past several months. Natarajan currently serves as SAIC’s Chief Financial Officer and brings deep enterprise leadership and extensive knowledge of SAIC’s business, customers, and strategy to his new role. As the Civilian Business Group leader, he will continue to build on the group’s momentum and advance SAIC’s growth and delivery for federal civilian customers. Natarajan will continue his role as Executive Vice President of Enterprise Operations and oversight of Project ORBIT.

Kenneth (Ken) Crews will join SAIC as Executive Vice President and Chief Financial Officer Elect. Crews is an accomplished finance executive with extensive experience driving enterprise performance, shaping business strategy, and enabling sustainable growth across complex organizations. He previously served as Corporate Vice President and Chief Financial Officer at Northrop Grumman, where he held several leadership roles during his more than 20 years with the company.

Crews will join SAIC on October 30, with Natarajan continuing to serve as Chief Financial Officer during the transition. Crews will formally assume the Chief Financial Officer role on December 7, 2026.

“SAIC has significant opportunities ahead, and having the right leaders in the right roles is critical to executing our strategy and accelerating growth,” said Jim Reagan, SAIC Chief Executive Officer. “Prabu has demonstrated strong leadership of our Civilian business and brings a deep understanding of our customers, our company, and the missions we support. Ken brings significant financial and operational leadership experience that will continue to help us drive performance and execute our strategy. I look forward to working with these accomplished leaders as we build on the momentum we have established and position SAIC for continued growth and long-term success.” 

The appointments come as SAIC continues to advance its strategy, invest in differentiated capabilities and talent, and focus on delivering greater value for customers and shareholders.

About SAIC
SAIC® is a premier mission integrator focused on advancing the power of technology and innovation to serve and protect our world. Our robust portfolio of offerings across the defense, space, intelligence, and civilian markets includes secure high-end solutions in mission IT, enterprise IT, engineering services, and professional services. We rapidly integrate emerging technologies into mission operations that modernize and enable critical national imperatives.

We are approximately 23,000 strong; driven by mission, united by purpose, and inspired by opportunities. Headquartered in Reston, Virginia, SAIC has annual revenues of approximately $7.3 billion. For more information, visit saic.com. For ongoing news, please visit our newsroom.

Media Contact
Caralyn Duke
Senior Manager, Media Relations
[email protected]

Investor Relations Contact
Jon Raviv
VP, Investor Relations
[email protected]

Forward-Looking Statements
Forward-Looking Statements Certain statements in this release contain or are based on “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “guidance,” and similar words or phrases. Forward-looking statements in this release may include, among others, estimates of future revenues, operating income, earnings, earnings per share, charges, total contract value, backlog, outstanding shares and cash flows, as well as statements about future dividends, share repurchases and other capital deployment plans. Such statements are not guarantees of future performance and involve risk, uncertainties and assumptions, and actual results may differ materially from the guidance and other forward-looking statements made in this release as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these material differences include those discussed in the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Legal Proceedings” sections of our Annual Report on Form 10-K, as updated in any subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, which may be viewed or obtained through the Investor Relations section of our website at saic.com or on the SEC’s website at sec.gov. Due to such risks, uncertainties and assumptions you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. SAIC expressly disclaims any duty to update any forward-looking statement provided in this release to reflect subsequent events, actual results or changes in SAIC’s expectations. SAIC also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jackson Financial Inc. (“Jackson Financial” or the “Company”) (NYSE: JXN).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Jackson Financial and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 17, 2026, QVT Financial LP published a short report alleging that Jackson Financial’s subsidiary, Jackson National Life, used an unusual installment arrangement with its captive reinsurer, Brooke Re, to mask massive hedge losses and inflate solvency metrics. 

Following publication of the report, Jackson Financial’s stock price fell $7.72 per share, or 5.63%, to close at $129.38 per share on September 17, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

What's wrong with Joby Aviation (JOBY -3.70%) stock? That's the question many investors are likely asking right now, with the stock plummeting more than 60% already in 2026. Last year, the stock was soaring, and there was plenty of optimism surrounding its future.

Today, however, investors appear to be much more cautious around the company, which hopes to one day be a leader in the electric vertical takeoff and landing (eVTOL) market. It hasn't obtained approval for its air taxi yet, but it has been making progress.

Joby's stock hit a new 52-week low on Tuesday, falling to less than $5. Given its promising growth potential, is it a no-brainer buy at this price point?

Image source: Getty Images.

Have investors gotten frustrated?Joby has been nearing FAA certification for its air taxi, but investors have been left waiting. Earlier this year, the company announced it had been selected as a partner for the White House's eVTOL Integration Pilot Program (eIPP), which the company hoped may have "the potential to significantly accelerate Joby's path to commercial service."

When the company released its most recent quarterly results in August, it stated it was in the final stage of FAA Type Certification. Despite all the test flights and progress, investors may be discouraged that the company has not yet launched commercial operations at this point. It has been demonstrating the effectiveness of its air taxis with test flights, but alas, investors may be eagerly awaiting the green light for when commercial operations actually commence.

Premium Feature

Moneyball Superscore

61/100

Today's Change

(

-3.70

%) $

-0.19

Current Price

$

4.95

Could Joby's stock take off before the end of 2026?Joby's stock is now trading around multi-year lows, levels it has been at since 2024. At a market cap of around $5 billion, it could make for an intriguing investment right now, given the potential for it to soar if its aircraft obtains approval from regulators, hopefully before the end of the year -- but that's by no means a guarantee.

Its inclusion in the eIPP should, however, give investors reason for some cautious optimism that Joby will inevitably commence operations. While there's no certainty as to when that might happen, once it does, the excitement around the stock could return, potentially making Joby a hot buy again.

Unfortunately, there's still a lot of risk with Joby's stock, because while it may have some enticing growth opportunities ahead, even if it does commence commercial operations, it may still be a long time before it has a path to profitability and is generating significant revenue.

For investors who are willing to be patient and who are comfortable with the risk, it may be worth buying. But for more risk-averse investors, this may be a stock more suitable to put on a watch list.

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against AST SpaceMobile, Inc. (“AST” or the “Company”) (NASDAQ: ASTS) and certain officers. The class action, filed in the United States District Court for the Western District of Texas, Midland-Odessa Division, and docketed under 26-cv-00378, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AST securities between March 4, 2025 and July 15, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired AST securities during the Class Period, you have until November 13, 2026 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

AST, together with its subsidiaries, designs and develops the constellation of BlueBird satellites in the United States (“U.S.”). The Company provides a cellular broadband network in space for direct access by smartphones for commercial use and other applications, as well as for government use. In addition, its SpaceMobile service provides cellular broadband services to end-users who are out of terrestrial cellular coverage.

At all relevant times, Defendants touted AST’s purportedly unique competitive advantages and leadership position in the satellite direct-to-cellular (“D2C”) market. In particular, throughout the Class Period, Defendants touted AST’s business and financial prospects as purportedly the only established space-based cellular broadband network for mobile phones.

Defendants’ assurances regarding AST’s purportedly durable competitive position in the satellite D2C market came into question in September 2025, when American telecommunications company EchoStar Corporation (“EchoStar”) announced that it had entered into a definitive agreement with SpaceX, an American aerospace manufacturer and space transportation company, to sell its AWS-4 and H-block spectrum licenses (the “EchoStar Transaction”). In connection with the EchoStar Transaction, SpaceX and EchoStar agreed to enter into a long-term commercial agreement, enabling EchoStar’s Boost Mobile subscribers—through its cloud-native 5G core—to access SpaceX’s next generation D2C service provided by its telecommunications subsidiary Starlink Services, LLC (“Starlink”).

SpaceX commands a dominant position in the global aerospace and orbital launch industry, with the ability to produce and launch numerous satellites at scale. Its subsidiary Starlink provides a broadband internet satellite constellation that accounts for roughly 54% of all active satellites in Earth’s orbit, with approximately 9,821 Starlink satellites currently active in low Earth orbit. Viewed in combination with its considerable resources, SpaceX’s entry into the satellite D2C market was potentially a threat to AST’s commercial aspirations.

Following the EchoStar Transaction, however, Defendants continued to assure investors and the market that AST remained in a competitive class of its own, with the Company poised to realize significant revenues and profits in the near-term. Likewise, Defendants continuously represented that AST’s capital and liquidity position was sufficient to meet its strategic and business goals at all relevant times, notwithstanding the heightened competitive pressures it faced following the EchoStar Transaction.

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) AST’s increasing capital requirements were likely to increase the Company’s debt load and share dilution with greater frequency and at greater scale than Defendants had signaled to investors; (ii) accordingly, Defendants had overstated the sufficiency of AST’s capital and liquidity position to achieve its strategic and business goals; (iii) Defendants likewise overstated the durability of AST’s competitive position in the satellite D2C market; (iv) even following the EchoStar Transaction, Defendants continued overstating AST’s competitive position in the satellite D2C market; (v) AST was experiencing slow user adoption in the U.S. and Japan; (vi) the foregoing was likely to have a significant negative impact on the Company’s business and financial prospects; and (vii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

The truth began to emerge on September 8, 2025, when UBS issued a report downgrading AST to a “Neutral” from “Buy” recommendation, as well as cutting its price target on the Company to $43.00 from $62.00, mainly citing heightened competitive pressures related to the EchoStar Transaction, which “fortifies [Starlink’s] position in the space to cellular market and increases risk for AST[] as it drives utilization on its nascent constellation[.]”

Following the release of UBS’s report, AST’s Class A common stock price fell $3.86 per share, or 9.47%, to close at $36.91 per share on September 9, 2025.

On October 21, 2025, AST issued a press release “announc[ing] its intent to offer . . . $850.0 million aggregate principal amount of convertible senior notes due 2036 (the ‘Notes’) in a private offering”, and that it “intends to grant the initial purchasers of the Notes . . . an option to purchase . . . up to an additional $150.0 million aggregate principal amount of Notes.” The press release disclosed that AST would use the proceeds from this offering “for general corporate purposes, including without limitation funding the deployment of AST SpaceMobile’s worldwide constellation of satellites in anticipation of adding incremental strategic markets for its SpaceMobile Service.”  (Emphasis added.)

Later the same day, AST issued another press release “announc[ing] the pricing of $1.0 billion aggregate principal amount of convertible senior notes due 2036 (the ‘Notes’) in a private offering”, noting that “[t]he size of the offering has been increased from the previously announced $850.0 million principal amount of Notes”, while reiterating the same intended use for the net proceeds from the offering.

Following these disclosures, AST’s Class A common stock price fell $7.26 per share, or 9.24%, to close at $71.35 per share on October 22, 2025.

On January 6, 2026, Scotiabank issued a report downgrading AST to a “Sell” recommendation, as well as its rating to “Sector Underperform” from “Sector Perform”, citing, inter alia, significant competition from Starlink and “[e]vidence of slow user adoption in the U.S. and Japan[.]”

Following the release of Scotiabank’s report, AST’s Class A common stock price fell $11.76 per share, or 12.06%, to close at $85.73 per share on January 7, 2026.

On February 11, 2026, AST issued a press release “announc[ing] its intent to offer . . . $1.0 billion aggregate principal amount of convertible senior notes due 2036 (the ‘Notes’) in a private offering”, and that it “intends to grant the initial purchasers of the Notes . . . an option to purchase . . . up to an additional $150.0 million aggregate principal amount of Notes.” The press release disclosed that AST intended to use the proceeds from the offering “for general corporate purposes, including without limitation, accelerating the deployment of our controlled spectrum bands on a global basis, monetizing the capabilities of our proprietary technology to capture the evolving commercial opportunities related to artificial intelligence, enhancing investment in government space opportunities in the U.S., reducing higher interest debt, and pursuing opportunistic investments to accelerate our SpaceMobile Service and capabilities.”  (Emphasis added.)

The next day, AST issued another press release announcing the pricing of the foregoing offering at “an initial conversion price of approximately $116.30 per share of AST SpaceMobile’s Class A common stock, which represents a premium of approximately 20% to the last reported sale price of AST SpaceMobile’s Class A common stock on February 11, 2026.”

Following these disclosures, AST’s Class A common stock price fell $14.70 per share, or 15.17%, to close at $82.22 per share on February 12, 2026. 

Then, on July 15, 2026, AST issued a press release “announc[ing] its intent to offer” yet another “$1.0 billion aggregate principal amount of convertible senior notes due 2034 (the ‘Notes’) in a private offering”, and that it “intends to grant the initial purchasers of the Notes . . . an option to purchase . . . up to an additional $150 million aggregate principal amount of Notes.” The press release disclosed that AST intended to use the proceeds from the offering to, inter alia, “pursue an expanding universe of growth initiatives and secure additional access to orbit for its space-based cellular broadband network, including partnerships and/or acquisitions to further vertically integrate its business and mitigate risks associated with third-party launch providers.” (Emphasis added.)  The press release further disclosed that the Company “currently does not have any understandings or agreements with respect to any such strategic transactions.”  (Emphasis added.)

Later the same day, AST issued another press release announcing the pricing of the foregoing offering. Specifically, “$1.0 billion 1.625% convertible senior notes due 2034 . . . [at] an initial conversion price of approximately $79.57 per share of AST SpaceMobile’s Class A common stock, which represents a premium of approximately 20.0% over the last reported sale price of AST SpaceMobile’s Class A common stock on July 15, 2026”, as well as “[c]apped call transactions . . . [at] an initial cap price of $149.20 per share of AST SpaceMobile’s Class A common stock, which represents a premium of 125.0% over the last reported sale price of AST SpaceMobile’s Class A common stock on July 15, 2026.”

Following the foregoing disclosures, AST’s Class A common stock price fell $11.30 per share, or 17.04%, to close at $55.01 per share on July 16, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising.  Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

Shares of clean energy company Oklo (OKLO -1.33%) are down big this year -- 55%. While the stock market has been doing well, Oklo's stock has been going in the opposite direction.

Many growth investors see significant growth potential for Oklo and believe it can benefit from opportunities related to investments in data centers for artificial intelligence (AI), which need reliable power sources. But that optimism appears to have faded, with the stock hitting a new 52-week low on Tuesday, at just above $31, a level it hasn't been at since May of last year.

The growth potential is still there for Oklo, but now its valuation is much lighter, with its market cap at just under $6 billion. Could now be an opportune time to buy this beaten-down energy stock?

Image source: Getty Images.

Oklo's mounting losses make the stock a risky optionIt may be multiple years before Oklo is generating any meaningful revenue, as its Aurora powerhouse at the Idaho National Laboratory is not expected to begin commercial operations until at least late next year. In the meantime, the company is incurring heavy losses and burning through cash.

Its operating loss through the first six months of the year totaled $124.2 million -- more than double the $45.9 million loss it posted during the same period a year ago. The reality is that as the business begins to scale and commences operations, its expenses may increase. As a result, it could take several years before the company may potentially be in a position to turn a profit.

For investors looking to own Oklo's stock, patience is definitely going to be a requirement.

Premium Feature

Moneyball Superscore

63/100

Today's Change

(

-1.33

%) $

-0.43

Current Price

$

31.78

The stock may look cheaper, but it may still not be worth buyingAt $6 billion, Oklo's valuation remains fairly high for a business that's in such an early stage of its development. It highlights just how egregiously overpriced it was beforehand. While it has come down significantly in value, there's still plenty of room for the stock to fall even lower.

Rising interest rates and concerns of an AI bubble may have investors less willing to take risks on AI-related investments. Oklo is among the riskiest options in that regard, as it's largely a speculative buy at this stage.

Oklo may inevitably fall further in the weeks and months ahead. It reaching a new 52-week low is by no means a great buying opportunity. Another 52-week low could, after all, be right around the corner.

This is a stock I'd take a wait-and-see approach with, as it's far too risky an option for most investors to even consider right now.

Key Takeaways Oscar Health shares gained 14.9% in three months, supported by strong membership growth and improved margins.OSCR's membership surged 46.2% to 2.96 million, while its first-half medical loss ratio improved to 75%.Oscar's SG&A ratio fell to 14.7% from 17.2%, aided by technology efficiencies and disciplined cost management. Oscar Health, Inc. (OSCR - Free Report) shares have gained 14.9% in the past three months, outpacing the broader market. The advance has coincided with rapid membership growth, better medical economics and lower administrative expense ratios.

The next test is execution. Oscar must sustain share gains and underwriting discipline while navigating Affordable Care Act (ACA) market contraction, membership cleanup, seasonality and a valuation that already reflects higher expectations.

Oscar's Share Gains Strengthen the Bull CaseOscar ended the second quarter of 2026 with 2.96 million members, up 46.2% year over year. That growth came even as broader ACA membership declined about 12%, indicating substantial share capture in a contracting market.

OSCR's Pricing Discipline Lifts Underwriting QualityOscar's first-half 2026 medical loss ratio improved to 75% from 83% a year earlier. Management attributed the improvement to disciplined pricing, stronger current-year performance and favorable prior-period reserve development.

That mix matters because membership growth is more valuable when medical costs remain controlled. Oscar expects a full-year 2026 medical loss ratio of 81%-82%, implying a higher second-half cadence but still reflecting better economics than the prior-year first half.

Oscar's Tech Leverage Adds Margin SupportThe first-half selling, general and administrative ratio fell to 14.7% from 17.2%. Fixed-cost leverage, disciplined expense management and technology-driven efficiencies helped expenses grow more slowly than the membership base.

Oscar also reported 98.7% first-pass claims accuracy, with most claims processed in under 48 hours. Artificial intelligence initiatives across benefits, billing, claims, clinical care and member support could add further scalability without proportionate headcount growth.

The Zacks Consensus Estimate for 2026 and 2027 EPS represents an increase of 208.3% and 21% respectively.

Image Source: Zacks Investment Research

Oscar's Ratings Back Growth but Momentum Is MixedThe three-month advance can continue if Oscar converts share gains into durable underwriting and operating leverage.

Oscar currently carries a Zacks Rank #1 (Strong Buy), which reflects favorable near-term earnings-estimate revision trends. It also has a VGM Score of A, Growth Score of A and Value Score of B, all favorable readings under the Style Score framework.

The Momentum Score of C is less supportive than an A or B and tempers the picture after the recent price gain. Continued fundamental execution therefore remains important even with a top Zacks Rank and favorable overall Style Scores.

Other Stocks to ConsiderElevance Health, Inc. (ELV - Free Report) and UnitedHealth Group (UNH - Free Report) are two other top-ranked stocks. Both carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for 2026 earnings of Elevance Health has moved north in the last 30 days while that for UnitedHealth witnessed no movement in the same time frame.

In terms of share price movement, Elevance Health and UnitedHealth Group have lost 1.1% and 11%, respectively, in the past three months.

A judge has ruled that Apple will gain expedited access to OpenAI’s hiring materials in the trade secrets-focused lawsuit the iPhone maker filed against OpenAI in July.

Specifically, the court will allow Apple to view documents associated with OpenAI’s interviews with former Apple employees who applied for roles within its consumer hardware and robotics groups ahead of the rumored launch of OpenAI’s first hardware device.

These documents could include interview checklists, guides, instructions, manuals, and scripts, as well as technical presentations and records showing that interview discussions had included references to Apple technology or components.

The court gave OpenAI five days to turn over materials it has already collected and 14 days for any other materials related to this request, agreeing with Apple that these documents should be expedited.

The case comes as OpenAI develops a consumer hardware device that could one day potentially rival the iPhone — or smartphones more generally — if the AI device becomes a central part of consumers’ lives and how they engage with software and services.

In its lawsuit, Apple accused OpenAI of a pattern of theft, which includes direct complaints about former employees using Apple laptops to download confidential material and files that contained information about unannounced technologies, features, and products, including technical specifications, engineering presentations, and proprietary project data.

Apple also said that former Apple employees at OpenAI coached others considering leaving Apple for OpenAI on what information to bring to their interviews, among other allegations.

U.S. District Judge Edward Davila didn’t greenlight all of Apple’s requests for expedited access to OpenAI documents and messages relevant to the case. But he did rule that Apple could access the interview materials, alongside private LINE messages (from a messaging app) between individuals named in the case, including OpenAI employees Chang Liu and Alyssa Peng.

The judge also approved depositions for Liu and Peng, along with a third individual, OpenAI’s chief hardware officer, Tang Yew Tan. All three are former Apple employees.

However, the judge denied Apple’s request to expedite its access to OpenAI’s research and development in specific areas, like metal finishes and power management. He also denied several of Apple’s broader discovery requests, like access to OpenAI’s hardware research or information about what its former employees created while working at OpenAI.

That denial isn’t final, though; the judge left the door open for Apple to narrow its requests and try again.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Sarah has worked as a reporter for TechCrunch since August 2011. She joined the company after having previously spent over three years at ReadWriteWeb. Prior to her work as a reporter, Sarah worked in I.T. across a number of industries, including banking, retail and software.

You can contact or verify outreach from Sarah by emailing [email protected] or via encrypted message at sarahperez.01 on Signal.

Scaleway's proposed Danish site will use HGX B300 systems to serve customers seeking EU-hosted AI capacity. Summary

Copenhagen expands Nvidia’s European distribution without establishing the size or timing of related sales.

Nvidia, the AI-computing and networking supplier NVDA, secured another planned Blackwell deployment through Scaleway's Copenhagen expansion, according to Reuters on October 13. Shares traded at $225.67, down 0.3%, at 10:29 a.m. ET. The project adds another European destination for Nvidia's hardware. But without a disclosed order value or system count, investors have little basis to calculate its contribution to sales.

The hardware packs plenty of muscle. Scaleway selected HGX B300, and Nvidia's documentation specifies eight Blackwell GPUs per baseboard, each carrying 288GB of memory. That totals 2.304TB of GPU memory per baseboard. Those specifications explain the computing capacity of each unit. They do not reveal the size of Scaleway's purchase. For investors, the missing numbers matter more than another impressive specification sheet.

Nvidia's GF Score of 95 out of 100 shows strong profitability and growth, while the weaker GF Value reading makes valuation the clear pressure point. That is the tension here: a powerful business can still carry a demanding price. European demand for locally hosted AI computing could widen Nvidia's customer base, but the next useful evidence is concrete—installation volumes, launch dates and follow-up orders. More deployment locations support the growth story; the dollars will determine how much this project matters.

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

Visa Inc (NYSE:V) stock hit new all-time highs this week, which is great news for investors in the credit card company. The news isn’t so good for Greg Abel, the man who succeeded Warren Buffett as CEO of Berkshire Hathaway Inc (NYSE:BRK)(NYSE:BRK).

Abel Sells Visa Stock EarlyAbel sold off the entire position in Visa stock in the first quarter of 2026, a stock that previously represented the 13th largest position in Berkshire’s investment portfolio at the end of 2025.

Berkshire Hathaway first bought Visa stock in the third quarter of 2011.

Taking the investment portfolio from 42 to 29 positions in the first quarter, Visa was one of many stocks cut in Abel’s first quarter as the CEO of the conglomerate.

Berkshire sold 8,297,460 V shares sometime in the first quarter. The filing does not disclose exactly when or at what price the sale happened; it only has to report which quarter the transaction occurred in.

Visa stock traded between $294.32 and $358.62 in the first quarter and ended the first quarter trading at $302.24 per share.

Based on the quarter’s trading range, the sale would have been between $2,441,278,681.20 and $2,975,635,105.20.

Today, the Visa position, if held, would be worth $3,264,220,764.

This means the Visa position sold in the first quarter cost Berkshire Hathaway $288.59 million to $822.94 million in profits compared with holding it now.

Read Next

Visa Stake HistoryWhile that sounds like a big miss, Abel has invested in other stocks and increased positions in other winners, which may have offset the losses from selling Visa early.

The Visa position was also a big winner for Berkshire Hathaway and sometimes the best investors take profits before the positions become losers. So in this case, Abel didn’t lose money on the Visa trade; he could have made even more if he’d held.

Berkshire Hathaway disclosed buying 2.29 million Visa shares on Nov. 14, 2011.

Over the years, Berkshire bought Visa stock nine times and sold it six times, according to data from Stock Circle.

This includes the conglomerate adding 573,000 more shares in the fourth quarter of 2011. The conglomerate then sold 2.53 million shares, or 88% of the position, in the first quarter of 2012.

The fund added to the Visa position in subsequent quarters, including a large 7.38 million-share purchase in the first quarter of 2015.

Before the recent sale, Berkshire’s last Visa transaction was selling 1.27 million shares in 2021.

Going back to the initial purchase of 2.29 million Visa shares in the third quarter of 2011. Those shares were bought at an average price between $19.81 and $23.21, adjusted for a 2015 stock split.

The shares were sold in the first quarter of 2026 in a range of $295.52 to $357.56.

This means Berkshire Hathaway made between 1,173.2% and 1,704.9% on its initial Visa shares.

Read Next

Photo by Primakov via Shutterstock

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

United Airlines is getting rid of one path to achieve elite status in 2027 and making its top tier harder to reach.

The Chicago-based airline is removing the ability for MileagePlus members to earn status partially based on flight segments flown in a calendar year for 2027. Instead, starting Jan. 1, United will only consider the number of points members earn based on Premier qualifying points earned from eligible flight spending, award travel and eligible United credit card spending.

United announced the change Tuesday in emails to MileagePlus members and on its website. The change aims to simplify how customers earn Premier status, according to the email obtained by CNBC that United sent to members.

Previously, members could gain status in the lowest elite tier, Premier Silver, with a combination of 15 flight segments and 5,000 points earned in a year, or with 6,000 points. Now, customers will only be able to achieve the status through points at the 6,000 point threshold.

The number of Premier qualifying points it will take for members to reach the Premier Gold and Platinum tiers through points will also stay the same as the previous points-only option. However, to reach United's highest rewards tier, Premier 1K, members now need 32,000 qualifying points, up from 28,000 in 2026.

Flyers earn one Premier qualifying point, or PQP, per dollar spent on United base fares and upgrades, and for every 100 miles they redeem for travel on United flights. United Chase cardholders also earn points when they spend money with their card.

MileagePlus members will still have to take at least four flights on United or United Express jets in a year to be eligible for Premier status.

In an interview with travel website The Points Guy, United's President of MileagePlus Jarad Fisher called the flight segments metric an "old relic," saying that the airline "thought it made more sense for them to have one consistent metric ... that they could focus on across the board between their flight activity, their engagement in the airline."

United also announced Tuesday that United cardholders who have Premier status will get a head start by automatically receiving 5% of the points needed to reach the status level they earned the previous year when a new year begins.

United earlier this year overhauled the way travelers earn miles to reward customers holding its credit cards. The carrier also slashed earnings for basic economy flights, following earlier changes to the same practice by American Airlines and Delta Air Lines. United previously upped the thresholds required to earn Premier status in 2024 for the 2025 qualification year.

UnitedHealth Group Inc. (NYSE:UNH) says its Medicaid business is bottoming and expects core Medicaid margins to improving after 2026.

UnitedHealthcare CEO Tim Noel told the company’s third-quarter earnings call that 2026 should be the trough year, now projected to be moderately better than minus 1%. Management said it expects margins to improve in 2027 and reach target levels by 2028.

UnitedHealth’s Medicare Advantage RatingsLast Friday, shares of health insurance companies, including UnitedHealth, traded higher after the U.S. Centers for Medicare & Medicaid Services (CMS) awarded five- and four-star ratings to plans offered by UnitedHealth, Clover Health Investments Corp (NYSE:CLOV) and Humana Inc. (NYSE:HUM).

This recognition comes as Humana reaffirmed its fiscal year 2026 adjusted EPS guidance and issued optimistic comments about fiscal years 2027 and 2028.

Network Adjustments Amid Rising CostsTo address rising costs, UnitedHealthcare and CVS Health Corp. (NYSE:CVS)‘s Aetna plan to tighten their Medicare Advantage networks by 2027.

In an Oct. 4 note, UnitedHealthcare President Bobby Hunter emphasized the need to respond to systemwide strain, citing higher medical and drug bills.

New Medicare Plans with $0 PremiumsTo expand access, UnitedHealthcare introduced its 2027 Advantage plans on Oct. 1, featuring $0 premiums and broader benefits.

The insurer aims to lower out-of-pocket costs and expand plan options for seniors. Over 94% of Medicare-eligible individuals will have access to a UnitedHealthcare plan, and 90% can choose a $0-premium plan.

The rollout includes updated UCard perks and $0 copays for primary care visits and Tier 1 prescription drugs.

Read also

UnitedHealth Raises Guidance: What It Means for XLV and Other Healthcare ETFs UnitedHealth Stock Wobbles Despite 61% Profit Jump, Boosted Outlook (CORRECTED) UnitedHealth Says Wall Street May Be Underestimating Its 2027 Earnings Potential Image: Shutterstock

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Micron (MU -3.62%) may be entering a new paradigm. The company operates in a cyclical industry, but Micron is taking steps to reduce its cyclicality over the next few years. This could transform Micron into a viable investment option and make it well worth buying stock in, as it looks ready to soar over the next few years.

But by how much? Let's take a look.

Image source: The Motley Fool.

A few comments guide Micron's trajectory
There has been no shortage of estimates regarding the strength of the artificial intelligence build-out. Some projections come from its peers and clients in the industry, while others come from its own management. During Micron's latest quarterly earnings report, management noted that they expect the "supply demand conditions to be much tighter in FY 2027 and 2028 than they were during 2026." That's a notable statement, as 2026's conditions were pretty tight. This led to soaring memory chip prices in 2026, and it could lead to even more expensive chips in the future.

However, Micron isn't sitting idle. It's racing to build more production facilities and expects its Idaho fabrication facility to begin producing chips in mid-2027, with its second Idaho facility starting production in late 2028. However, Micron still projects that memory chips will be in short supply. So, if Micron can increase its output dramatically while maintaining today's high prices, it could lead to incredible growth for the company. But it's not done there.

Premium Feature

Moneyball Superscore

91/100

Today's Change

(

-3.62

%) $

-35.85

Current Price

$

953.19

Micron is starting to sign long-term customer agreements that are locking in floor and ceiling prices for memory chips through 2030. These are also take-or-pay agreements, so Micron is locking in revenue streams. Some of these agreements extend into 2031, indicating an even longer AI growth trajectory.

One long-term AI growth trajectory projection comes from Nvidia, which has repeatedly told investors to expect $3 trillion to $4 trillion in global AI data center capital expenditures annually by 2030. In 2026, Nvidia expects the big five AI hyperscalers to spend nearly $800 billion. If you estimate what others beyond the big five are spending, it's easy to see total capital expenditures sitting around $1 trillion this year.

So, the AI market could triple by 2030. This has huge implications for Micron, as its stock could be ready to skyrocket.

Micron is cheap and has huge growth
First off, Micron has hardly any growth priced into its stock for next year. It only trades at 5.6 times forward earnings.

MU PE Ratio (Forward) data by YCharts

The market is still pricing in a cyclical downturn in the near future, even though Micron has already told investors it won't happen anytime soon. This could lead to the stock at least tripling by the end of 2027, simply by rising to a reasonable valuation. Combine that with the AI market tripling to quadrupling as a whole by 2030, and there is a massive amount of upside baked into the stock.

So, how much could a $2,500 investment in Micron be worth by 2030? If all of the projections stated above come true, when Micron's fabrication facilities come online and start producing a large number of chips as expected, I think investors can expect the stock to grow more than 5-fold. How? First, Micron starts to trade at a reasonable 20 times earnings. I think this is somewhat realistic, as Micron has entered into long-term purchasing agreements with its clients that will reduce the effects of cyclical downturns. As a result, the market will give it a more respectable premium. That takes care of the stock rising about threefold to fourfold.

For the remainder of its growth, I'd point toward Nvidia's projection that data center capital expenditures will triple to quadruple by the time 2030 rolls around. That will mostly be from more computing chips needed, and every computing chip needs memory, potentially sourced from Micron. With that much growth ahead, I think it's pretty reasonable to expect Micron's business to double or triple. That would suggest a $2,500 investment in Micron could be worth $12,500, which makes the stock an absolute no-brainer buy at today's prices.

Micron is taking steps to ensure it isn't as cyclical, and this could make it a strong investment in the AI revolution.

RAPID CITY, S.D., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Black Hills Corp. (NYSE: BKH) today announced that its natural gas utility subsidiary in Arkansas received approval from the Arkansas Public Service Commission of new rates. The new rates will provide recovery of approximately $147 million of system investments since the utility’s last general rate filing in 2023 and operational costs required to deliver safe, reliable natural gas service for over 189,000 Arkansas customers in more than 100 communities in Arkansas.

“This approval supports our ability to deliver on our commitment to serve our Arkansas customers with the safe and reliable natural gas service they depend on and support ongoing growth needs in the state,” said Linn Evans, president and CEO of Black Hills Corp. “We are proud of our solid track record of delivering for the needs of our customers, and we remain diligently focused on maintaining dependable natural gas service in Arkansas.”

The new rates will generate approximately $17.9 million of new annual revenues. The new rates, effective Oct. 12, 2026, are based on a return on equity of 9.8% and capitalization of 47.5% equity and 52.5% debt.

Black Hills Corporation
Black Hills Corp. (NYSE: BKH) is a customer-focused, growth-oriented utility company with a tradition of improving life with energy and a vision to be the energy partner of choice. Based in Rapid City, South Dakota, the company serves 1.37 million natural gas and electric utility customers in eight states: Arkansas, Colorado, Iowa, Kansas, Montana, Nebraska, South Dakota and Wyoming. More information is available at www.blackhillscorp.com.

Investor Relations
Sal Diaz
605-399-5079
[email protected]

24-Hour Media Relations Line
888-242-3969

Caution Regarding Forward-Looking Statements
This news release includes “forward-looking statements” as defined by the Securities and Exchange Commission, or SEC. We make these forward-looking statements in reliance on the safe harbor protections provided under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this news release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements, including anticipated revenues from the new rate increase. These forward-looking statements are based on assumptions which we believe are reasonable based on current expectations and projections about future events and industry conditions and trends affecting our business. However, whether actual results and developments will conform to our expectations and predictions is subject to a number of risks and uncertainties that, among other things, could cause actual results to differ materially from those contained in the forward-looking statements, the risk factors described in Item 1A of Part I of our 2025 Annual Report on Form 10-K filed with the SEC, and other reports that we file with the SEC from time to time.

New factors that could cause actual results to differ materially from those described in forward-looking statements emerge from time-to-time, and it is not possible for us to predict all such factors, or the extent to which any such factor or combination of factors may cause actual results to differ from those contained in any forward-looking statement. We assume no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or otherwise.

-

HOUSTON & MIDLAND, Texas--(BUSINESS WIRE)--Kinetik Holdings Inc. (NYSE: KNTK) (“Kinetik” or the “Company”) has declared a cash dividend of $0.81 per share, or $3.24 per share on an annualized basis. The announced quarterly dividend will be paid on Friday, October 30, 2026 to shareholders of record as of market close on Friday, October 23, 2026.

Kinetik will host its third quarter 2026 results conference call on Thursday, November 5, 2026 at 8:00 am Central Time (9:00 am Eastern Time). The Company will issue its earnings release after market close on Wednesday, November 4, 2026. The text of the earnings release, the accompanying presentation and link to the live webcast will be available on the Company’s website at www.ir.kinetik.com. A replay of the conference call will be available on the website following the call.

Kinetik previously implemented a Dividend Reinvestment Plan (the “DRIP” or the “Plan”) open to all shareholders. A complete description of the Plan is included in the Company’s Form S-3 registration statement filed with the SEC on July 12, 2024 and is posted on the Company’s website at www.kinetik.com.

To participate, shareholders of record may register online by visiting the Broadridge website at shareholder.broadridge.com/KNTK or by contacting Broadridge Corporate Issuers, LLC, the Plan Administrator, by telephone toll free from inside the United States at 1-(877)-830-4936 or outside of the United States at 1-(720)-378-5591. Shareholders may also contact the Plan Administrator in writing at Broadridge Shareholder Services, Broadridge Corporate Issuer Solutions, LLC, PO Box 1342, Brentwood, NY 11717-0718. Please include a reference to Kinetik Holdings Inc. in all correspondence. Shareholders who own common stock through a broker should consult their broker regarding participation in the Plan.

About Kinetik Holdings Inc.

Kinetik is a fully integrated, pure-play, Permian-to-Gulf Coast midstream C-corporation operating in the Delaware Basin. Kinetik is headquartered in Houston and Midland, Texas. Kinetik provides comprehensive gathering, transportation, compression, processing and treating services for companies that produce natural gas, natural gas liquids, crude oil and water. Kinetik posts announcements, operational updates, investor information and press releases on its website, www.kinetik.com.

More News From Kinetik Holdings Inc.

Back to Newsroom

New York, New York--(Newsfile Corp. - October 13, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against AppLovin Corporation ("AppLovin" or the "Company") (NASDAQ: APP) on behalf of investors that purchased or otherwise acquired AppLovin securities between February 12, 2026 and August 5, 2026 (the "Class Period").

CLICK HERE TO JOIN THE CASE

If you are an investor in AppLovin and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 16, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that "(i) the generative AI video creative feature for the Company's AppLovin Ads platform was subject to significant development delays, making its release on the Company's timeline unlikely," and "(ii) Defendants overstated the constancy with which AppLovin was improving its AI models."

According to the complaint, the truth began to emerge on July 13, 2026, when a Bank of America Securities analyst published a note raising concerns over the rollout of AppLovin Ads to all advertisers. Following publication of the note, AppLovin's stock price fell $64.13 per share, or 12.65%, on July 13, 2026. Then, on August 5, 2026, according to the complaint, AppLovin reported revenue below consensus estimates and also revealed that its generative AI video tool was "still [a] work in progress." On this news, AppLovin's stock price fell $82.13 per share, or 19.66%, on August 6, 2026.

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/applovin-nasdaq-app-class-action-lawsuit-learn-more-now/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/318761

Source: Kaplan Fox & Kilsheimer LLP

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Phased Updates Include New Leave Management, Recruiting and Business Spending Capabilities

, /PRNewswire/ -- TriNet (NYSE: TNET) a leading provider of comprehensive human resources solutions for small and medium-size businesses (SMBs) today announced new and enhanced platform capabilities designed to reduce administrative complexities. The latest updates provide HR capabilities that SMBs really need, including embedded solutions that simplify recruiting, leave management and business spending, and expanded AI-powered intelligence to help businesses access and analyze information, and complete tasks more efficiently.

TriNet Expands Embedded HR Solutions and AI Capabilities for Small and Medium-Size Businesses "Business owners no longer want to simply react to change; they want to stay ahead of it," said Jeff Hayward, EVP and Chief Service and Technology Officer at TriNet. "That's why we're continuing to invest in AI-powered intelligence and more connected experiences that help our customers make decisions faster, reduce administrative work and focus more of their time on growing their businesses."

"Our customers don't think about HR in silos, and their technology shouldn't work that way either," said Lisa Reeves, Chief Product Officer at TriNet. "These enhancements bring together trusted technology, embedded partner solutions and TriNet's HR expertise to make it easier for our customers to hire, support their people, manage their business and make confident decisions." 

TriNet is introducing the latest enhancements in phases, creating more connected experiences across critical business functions while continuing to expand AI-powered capabilities that help businesses work more efficiently. These include:

TriNet Leave, Powered by Cocoon: Following TriNet's acquisition of Cocoon earlier this year, TriNet is introducing TriNet Leave, powered by Cocoon, a modern leave management experience connected to the TriNet platform and now rolling out in phases. By combining Cocoon's technology with TriNet's leave administration expertise, the solution helps employers manage leave requests, compliance obligations, claims tracking and return-to-work processes through a single intuitive experience. Customers benefit from greater visibility, automation and guidance while helping navigate increasingly complex leave requirements. TriNet Recruit, Powered by JazzHR: Available in early January, TriNet Recruit will provide growing businesses with a structured applicant tracking experience that helps simplify hiring from job posting to onboarding. Customers can organize candidates, collaborate on hiring decisions, extend offers, and move employee information into onboarding through a connected workflow. TriNet Spend: Available in early January, TriNet Spend will connect employee, payroll and spending data into a unified experience through an integrated technology partnership. The solution helps small businesses gain greater visibility and control over company expenses, while automated workflows and payroll-connected reimbursements reduce manual work and deliver real-time insights and control of spending. AI-Powered Assistance: Building on the success of TriNet Assistant, and available now, TriNet continues to expand its AI-powered capabilities to help customers find information, gain workforce insights, and complete everyday tasks more efficiently. New enhancements include voice-enabled mobile experiences and expanded AI capabilities for administrators, including the ability to ask questions about workforce data directly within Reports and Analytics. To learn more about TriNet's updates, visit us online at https://www.trinet.com/launch.

About TriNet
TriNet is a leading provider of human resources solutions for small and medium-size businesses, delivering what they really need from HR: expertise, technology and advocacy that make it easier to run and grow their business. Through advanced technology-enabled services and deep human capital expertise, TriNet provides access to employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. TriNet helps businesses navigate the complexities of HR so they can focus on why they started their companies in the first place. For more information, visit TriNet.com or follow us on LinkedIn, Instagram, TikTok and Facebook

SOURCE TriNet

Key Takeaways DexCom's second-quarter 2026 gross margin rose to 64.1%, while operating margin climbed to 25.1%.Nearly 50% of U.S. customers are expected to transition to G7 15-day by year-end 2026.Ireland factory costs, forex headwinds and higher oil-linked input costs could limit near-term margin gains. DexCom, Inc. (DXCM - Free Report) is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong first-quarter 2026 performance and a robust international foothold are expected to contribute further. Risks related to stiff competition persist.

This Zacks Rank #3 (Hold) company’s shares have gained 29.4% so far this year against the industry’s 5.7% decline. The S&P 500 Index has gained 13.9% in the same time frame.

DXCM, a renowned medical device company and provider of CGM systems, has a market capitalization of $31.74 billion. It projects a 22.6% growth rate over the next five years and anticipates maintaining a strong performance going forward.

DexCom’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 11.39%.

Let’s delve deeper.

Image Source: Zacks Investment Research

Positive DriversManufacturing Efficiencies and Operating Leverage Boost Profitability: DexCom’s improving manufacturing efficiency and operating discipline are supporting stronger earnings growth. In the second quarter of 2026, gross margin expanded 400 basis points year over year to 64.1%, while operating margin increased to 25.1% from 19.2%.

Operating expenses grew at a slower pace than revenues, demonstrating improved operating leverage even as the company invested in its Ireland facility. Management also raised its full-year gross margin guidance to approximately 64% and operating margin guidance to 23.5-24%. Sustaining these improvements could allow DexCom to convert incremental revenues to stronger operating income, although upcoming manufacturing investments may temporarily moderate the gains.

G7 15-Day Conversion Creates a Multiyear Product-Mix Opportunity: DexCom’s G7 15-day system is progressing toward a substantial shift in its U.S. product mix. Management expects nearly 50% of its U.S. customer base to transition to the system by the end of 2026. A greater contribution to profitability is expected in 2027 as more customers establish recurring purchasing patterns.

The rollout has also benefited from improved customer feedback, with G7 Net Promoter Scores rising for three consecutive quarters. Integration with Tandem’s insulin-delivery systems has removed an important adoption barrier, while Health Canada’s clearance provides a path to international expansion. The transition could therefore support sustained top- and bottom-line improvement beyond the current year.

Smart Basal and G8 Expand DexCom’s Longer-Term Innovation Potential: DexCom’s product pipeline could strengthen its competitive positioning beyond existing continuous glucose monitoring applications. Its Smart Basal dosing module is being piloted with key opinion leaders, and management reported that participating practices helped customers reach an optimal basal insulin dose in an average of three weeks, compared with 12 weeks or longer in routine care.

Meanwhile, the G8 sensor remains on track for late 2027 or early 2028, subject to regulatory timing. Management expects improvements in accuracy and reliability, reduction in size to approximately half of G7, and eventual expansion into additional analytes. Successful execution could broaden clinical utility and create new opportunities in diabetes management and metabolic health.

RisksIreland Factory Ramp-Up Could Temporarily Pressure Margins: DexCom’s margin expansion may face a near-term interruption as its Ireland manufacturing facility moves toward commercial production. Hiring and training should have increased in the third quarter before production lines become operational, with depreciation also beginning during the ramp-up.

A newly activated factory typically carries higher per-unit manufacturing costs until production volumes improve and fixed costs are absorbed more efficiently. Consequently, the facility’s initial operating burden could offset some of the benefits from manufacturing efficiencies and the G7 15-day product transition. While the investment is intended to support future capacity, the pace of production ramp-up will be key to near-term profitability.

Forex Movements Could Limit Reported Revenue Growth: Currency movements represent a measurable headwind to DexCom’s reported revenue outlook. Although management raised its full-year revenue guidance to $5.18-$5.25 billion, it expects recent foreign-exchange movements to reduce international revenues by approximately $15 million in the second half of 2026 relative to its previous assumptions. This creates a potential divergence between underlying operating performance and reported growth, particularly because international markets account for a meaningful portion of sales.

Management noted that the revised guidance still implies an improvement in expected organic growth, but investors will need to distinguish constant-currency performance from reported results when evaluating the company’s progress.

Higher Oil-Linked Input Costs Could Weigh on Near-Term Profitability: DexCom remains exposed to delayed input-cost pressure from higher oil prices because petroleum-based resins take time to move through procurement, manufacturing, inventory accounting and reported expenses. Management indicated that some of this impact had already flowed through in the second quarter, with additional effects expected in the third quarter.

Although the company said the headwind was broadly consistent with prior expectations, this exposure could constrain further margin expansion if input costs remain elevated or operational improvements fail to fully offset them. The risk is particularly relevant during the Ireland facility ramp-up, when incremental manufacturing costs could coincide with lingering resin-price pressure.

Estimate TrendDexCom has witnessed a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share has remained unchanged at $2.64.

The consensus mark for the company’s third-quarter revenues is pegged at $1.32 billion, indicating a 9.4% improvement from the year-ago quarter’s reported number. The consensus estimate for third-quarter earnings is pinned at 66 cents per share, implying an improvement of 8.2% year over year.  

Stocks to ConsiderSome better-ranked stocks from the broader medical space are AxoGen (AXGN - Free Report) , Globus Medical (GMED - Free Report) andWest Pharmaceutical Services (GKOS - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

AxoGen reported second-quarter 2026 earnings per share (EPS) of 12 cents, which surpassed the Zacks Consensus Estimate by 33.3%. Revenues of $70 million beat the Zacks Consensus Estimate by 4.3%. AXGN has an estimated earnings growth rate of 48.4% for 2026, likely followed by another strong growth of 60.9% in 2027. The company’s earnings beat estimates in two of the trailing four quarters and missed in the other two, the average surprise being 6.25%.

Globus Medical reported second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.

MongoDB Inc (NASDAQ:MDB), the US database software company, has retained a 'Buy' rating from Bank of America Securities and $540 price target, with the broker citing its long-term growth prospects in artificial intelligence and enterprise modernisation.

Analysts reaffirmed the rating following an investor meeting with management, highlighting MongoDB’s document-based database technology as a differentiated platform for businesses modernising their systems and developing AI applications.

The broker sees Atlas Infinite, MongoDB’s platform designed to let computing power and storage capacity scale independently, as a potential catalyst for adoption of AI workloads that require flexible infrastructure.

The platform is intended to support agentic artificial intelligence, in which software systems can perform tasks and take actions with limited human intervention, creating potential demand for databases that can respond to changing workloads.

Bank of America’s assessment reflects MongoDB’s long-term targets for annual revenue growth above 20% and generally accepted accounting principles (GAAP) profitability from 2027.

The broker raised its revenue forecasts for financial 2028 by 3% to $3.65 billion and for financial 2029 by 6% to $4.39 billion, reflecting greater confidence in the company’s growth trajectory.

It also increased its projected non-GAAP operating margins to 21.9% for financial 2028 and 22.9% for financial 2029, signalling expectations of improving profitability as revenue expands.

However, the leadership transition remains a near-term risk, while competition from traditional database providers such as PostgreSQL continues to shape investor debate over MongoDB’s competitive advantages.

Bank of America will monitor Atlas revenue growth and net revenue retention, which measures spending changes among existing customers, for evidence that Atlas Infinite is translating into sustained customer adoption.

The $540 price target reflects the broker’s confidence that MongoDB can combine AI-related demand with enterprise modernisation to deliver durable revenue growth and margin expansion.